Login to Your Account



Pharmacopeia's JAK3 Program Subject Of $189M Wyeth Deal

By Jennifer Boggs


Friday, January 5, 2007
Pharmacopeia Drug Discovery Inc. could receive up to $189 million in a deal with Wyeth Pharmaceuticals to develop compounds inhibiting JAK3, a target that has gained interest over the last few months in the area of inflammatory disease. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription